| 000 | 01496 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250512200313.0 | ||
| 264 | 0 | _c19840802 | |
| 008 | 198408s 0 0 eng d | ||
| 022 | _a0010-440X | ||
| 024 | 7 |
_a10.1016/0010-440x(84)90056-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEllison, J M | |
| 245 | 0 | 0 |
_aPsychopharmacologic approaches to borderline syndromes. _h[electronic resource] |
| 260 |
_bComprehensive psychiatry _c |
||
| 300 |
_a255-62 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAnger _xdrug effects |
| 650 | 0 | 4 |
_aAntidepressive Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAntipsychotic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAnxiety _xcomplications |
| 650 | 0 | 4 |
_aAttention Deficit Disorder with Hyperactivity _xdrug therapy |
| 650 | 0 | 4 |
_aBorderline Personality Disorder _xcomplications |
| 650 | 0 | 4 |
_aCognition Disorders _xcomplications |
| 650 | 0 | 4 |
_aEpilepsy, Temporal Lobe _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMonoamine Oxidase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aMood Disorders _xcomplications |
| 650 | 0 | 4 |
_aNeurocognitive Disorders _xdrug therapy |
| 650 | 0 | 4 |
_aPersonality Disorders _xcomplications |
| 650 | 0 | 4 |
_aSchizophrenia _xcomplications |
| 650 | 0 | 4 |
_aSchizotypal Personality Disorder _xdiagnosis |
| 700 | 1 | _aAdler, D A | |
| 773 | 0 |
_tComprehensive psychiatry _gvol. 25 _gno. 3 _gp. 255-62 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0010-440x(84)90056-7 _zAvailable from publisher's website |
| 999 |
_c6145620 _d6145620 |
||